drugset / Trial / NCT06440824

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

NCT06440824

Phase 3 Unknown 60 enrolled Shandong University
RandomizedParallel-groupOpen-labelTreatment

Summary

A Multicenter Randomized Controlled Study on the Treatment of Refractory CTIT With Romiplostim N01 Compared to Recombinant Human Thrombopoietin

Timeline

Start
2024-06-01
Primary completion
2025-06-01
Completion
2025-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Romiplostim N01 Peptide 2 ug/kg Subcutaneous
Comparator recombinant human thrombopoietin Protein / enzyme biologic 30000 iu Subcutaneous

Indications